India's Ranbaxy gets US okay for antihistamine tablets
April 12 (Reuters) - India's Ranbaxy Laboratories Ltd. (RANB.BO: Quote, Profile, Research, Stock Buzz) said it got U.S. Food and Drug Administration approval to market Loratadine antihistamine tablets.
Ranbaxy's Loratadine tablets are bioequivalent to Claritin Reditabs of Schering Plough Healthcare Products, the U.S. over-the-counter and consumer products business unit of Schering-Plough Corp. (SGP.N: Quote, Profile, Research, Stock Buzz). (Reporting by Rakesh Sharma in Bangalore)
© Thomson Reuters 2008 All rights reserved
Help us advance this story. Provide relevant links or share your insights using our comment box. Please be considerate and help us by reporting any abuse you find. Reuters will delete comments that don't meet community standards.
Have a correction to this article? Email the editors
Cash injection
Bush: G7 needs coordination